Phillip Md Et Al Frost Purchases 12,200 Shares of Opko Health Inc. (OPK) Stock

Opko Health Inc. (NASDAQ:OPK) CEO Phillip Md Et Al Frost purchased 12,200 shares of the firm’s stock in a transaction dated Thursday, March 23rd. The stock was purchased at an average cost of $7.71 per share, with a total value of $94,062.00. Following the acquisition, the chief executive officer now directly owns 3,068,951 shares in the company, valued at $23,661,612.21. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Phillip Md Et Al Frost also recently made the following trade(s):

  • On Friday, March 24th, Phillip Md Et Al Frost purchased 3,600 shares of Opko Health stock. The stock was purchased at an average cost of $7.75 per share, with a total value of $27,900.00.
  • On Tuesday, March 21st, Phillip Md Et Al Frost purchased 5,800 shares of Opko Health stock. The stock was purchased at an average cost of $7.85 per share, with a total value of $45,530.00.
  • On Monday, March 20th, Phillip Md Et Al Frost purchased 11,000 shares of Opko Health stock. The stock was purchased at an average cost of $7.99 per share, with a total value of $87,890.00.
  • On Friday, March 17th, Phillip Md Et Al Frost purchased 9,000 shares of Opko Health stock. The stock was purchased at an average cost of $8.19 per share, with a total value of $73,710.00.
  • On Wednesday, March 15th, Phillip Md Et Al Frost bought 1,800 shares of Opko Health stock. The stock was bought at an average cost of $8.03 per share, with a total value of $14,454.00.
  • On Friday, March 10th, Phillip Md Et Al Frost bought 1,800 shares of Opko Health stock. The stock was bought at an average cost of $7.97 per share, with a total value of $14,346.00.
  • On Thursday, March 9th, Phillip Md Et Al Frost bought 3,600 shares of Opko Health stock. The stock was bought at an average cost of $7.84 per share, with a total value of $28,224.00.
  • On Wednesday, March 8th, Phillip Md Et Al Frost bought 1,800 shares of Opko Health stock. The stock was bought at an average cost of $7.92 per share, with a total value of $14,256.00.
  • On Friday, March 3rd, Phillip Md Et Al Frost bought 8,600 shares of Opko Health stock. The stock was bought at an average cost of $7.43 per share, with a total value of $63,898.00.
  • On Thursday, March 2nd, Phillip Md Et Al Frost bought 94,800 shares of Opko Health stock. The stock was bought at an average cost of $7.53 per share, with a total value of $713,844.00.

Shares of Opko Health Inc. (NASDAQ:OPK) opened at 8.14 on Tuesday. Opko Health Inc. has a 12 month low of $7.13 and a 12 month high of $12.15. The firm’s 50-day moving average is $8.15 and its 200 day moving average is $9.56. The company’s market capitalization is $4.54 billion.

Opko Health (NASDAQ:OPK) last released its quarterly earnings results on Wednesday, March 1st. The company reported ($0.04) earnings per share (EPS) for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.04). The firm earned $275.50 million during the quarter, compared to the consensus estimate of $310.82 million. Opko Health had a negative net margin of 0.81% and a negative return on equity of 0.49%. The business’s revenue was down .3% compared to the same quarter last year. Equities research analysts predict that Opko Health Inc. will post ($0.10) EPS for the current year.

Insider Buying and Selling by Quarter for Opko Health (NASDAQ:OPK)

TRADEMARK VIOLATION WARNING: “Phillip Md Et Al Frost Purchases 12,200 Shares of Opko Health Inc. (OPK) Stock” was originally reported by Mideast Time and is the property of of Mideast Time. If you are reading this story on another site, it was copied illegally and republished in violation of U.S. & international copyright & trademark laws. The correct version of this story can be viewed at https://www.mideasttime.com/phillip-md-et-al-frost-purchases-12200-shares-of-opko-health-inc-opk-stock/1590412.html.

A number of equities analysts recently weighed in on OPK shares. Guggenheim started coverage on shares of Opko Health in a research note on Tuesday, March 14th. They issued a “buy” rating and a $25.00 target price for the company. Standpoint Research reaffirmed a “buy” rating and issued a $14.00 target price on shares of Opko Health in a research note on Sunday, March 5th. Laidlaw reaffirmed a “buy” rating and issued a $19.00 target price (down from $22.00) on shares of Opko Health in a research note on Tuesday, January 3rd. Ladenburg Thalmann Financial Services reaffirmed a “buy” rating and issued a $19.50 target price (down from $20.00) on shares of Opko Health in a research note on Tuesday, January 3rd. Finally, TheStreet lowered shares of Opko Health from a “c-” rating to a “d+” rating in a research note on Wednesday, February 1st. One research analyst has rated the stock with a sell rating, three have given a hold rating and six have issued a buy rating to the company’s stock. Opko Health presently has a consensus rating of “Buy” and an average price target of $15.69.

Institutional investors have recently added to or reduced their stakes in the stock. Norges Bank acquired a new position in Opko Health during the fourth quarter valued at about $30,421,000. State Street Corp increased its position in Opko Health by 3.0% in the fourth quarter. State Street Corp now owns 7,787,875 shares of the company’s stock valued at $72,427,000 after buying an additional 226,132 shares during the last quarter. Whalerock Point Partners LLC acquired a new position in Opko Health during the third quarter valued at about $2,100,000. Piedmont Investment Advisors LLC acquired a new position in Opko Health during the third quarter valued at about $622,000. Finally, Russell Investments Group Ltd. acquired a new position in Opko Health during the fourth quarter valued at about $648,000. 22.58% of the stock is owned by hedge funds and other institutional investors.

About Opko Health

OPKO Health, Inc (OPKO) is a healthcare company. The Company operates through two segments: diagnostics and pharmaceutical. The pharmaceutical segment consists of its pharmaceutical operations in Chile, Mexico, Ireland, Israel and Spain, and its pharmaceutical research and development operations. The diagnostics segment primarily consists of its clinical laboratory operations.

5 Day Chart for NASDAQ:OPK

Receive News & Ratings for Opko Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opko Health Inc. and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply

 
© 2006-2017 Mideast Time.